Articles
Top Ten Red Flags to Look for in Your Brand License Agreement
This article outlines red flags that brand owners and licensees should look for, consider, and address if they find such flags in a brand license agreement.
This article outlines red flags that brand owners and licensees should look for, consider, and address if they find such flags in a brand license agreement.
IP practitioners do not view themselves as typically in the crosshairs of political and national security issues. But the Russian invasion of Ukraine offers many lessons learned from the perspective of how to prepare for any future sanctions or political pressure, and what to do if such actions are taken.
This Wisdom of the Crowd, compiled from responses posted on the Compliance and Ethics forum addresses paid time off requests with ADA accommodations.
This policy outlines the guidelines for delegating authority within a business entity to ensure efficient operations while maintaining fiscal and policy integrity.
This Wisdom of the Crowd, compiled from questions and responses posted on the IT, Privacy and eCommerce eGroup, addresses the legal concerns that arise when taking photographs of employees and non-employees at company events, to be used for marketing and other promotional purposes by the organization in the United States.
Learn about privacy rights and information protection provided by South Africa's Protection of Personal Information Act 4.
Learn about recent cybersecurity and data protection legislation in China and related security assessments, certification or standard contracts, and restrictions.
Learn about the Mauritian Data Protection Act 2017 provisions on data transfer and portability as compared with GDPR.
Learn about the recent Security Assessment Measures in China and their provisions for three approaches to cross-border transfers of personal information.
The Personalized Medicine Coalition (PMC) recently released its annual report on the progress of precision medicine as measured by precision medicine FDA approvals in 2022 (“Report”). As summarized in the Report, 2022 milestones include progress in diagnostics, therapeutics and new treatment modalities that are covered in this resource from Foley and Lardner LLP.